Sjögren's Fatigue: Evidence-Based Natural Treatment Guide

Sjögren's fatigue is real, physiological, and the most common complaint in the disease. Ng and Bowman's 2010 review in Rheumatology called the syndrome "too dry and too tired" for a reason: in primary Sjögren's, patients consistently rate fatigue as more debilitating than dryness itself. Roughly 70% describe it as moderate to severe on visual analog scales (Segal 2008). The EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI) weights fatigue equally with pain and dryness, treating it as a defining feature of the disease rather than a side effect. If your rheumatologist has told you there is nothing to do about the exhaustion, the literature disagrees. Discuss any new intervention, particularly LDN, TGP, or prescription changes, with your rheumatologist before starting.

This guide assumes you are already diagnosed and have read the Sjögren's natural treatment pillar. It focuses specifically on fatigue: why it happens, how to tell which of five causes is driving yours, which interventions have real evidence, and which ones do not.

Why Sjögren's Fatigue Feels Different

Most tired people feel better after a night of sleep. Sjögren's patients do not. The exhaustion is post-activation rather than post-exertional in the strict ME/CFS sense: mental effort, social time, a short walk, any activation of the system can trigger hours or days of disproportionate wipeout. Patients describe it as "sicca fog," a cognition that feels thick or slow, sometimes paired with a physical heaviness in the limbs that no caffeine reaches.

The mechanism behind this is measurable. Bodewes et al. (2018) documented hyperresponsive monocytes in primary Sjögren's patients producing elevated IL-6 and type I interferon on stimulation. Davies et al. (2019) tied type I IFN signatures to sickness-behavior pathways in the central nervous system, the same pathways activated during viral illness. The body reads the cytokine environment and responds with the behavioral signature of infection: lethargy, cognitive slowing, social withdrawal, appetite shift.

This is why sleep alone does not fix it, why standard stimulants mask without addressing, and why the disease-specific interventions (TGP, LDN, hydroxychloroquine) target immune signaling rather than energy metabolism directly.

The 5 Root Causes of Sjögren's Fatigue

Sjögren's patients carry a baseline cytokine fatigue from the disease itself. They also accumulate secondary contributors at rates higher than the general population. A fatigue workup that stops at "you have Sjögren's, of course you're tired" misses four treatable conditions that often carry more of the load than the autoimmunity does.

1. Primary Autoimmune Cytokine Fatigue (IL-6 / Interferon Signature)

This is the baseline. Elevated IL-6, type I IFN activity, and TNF-alpha signaling produce the sickness-behavior phenotype regardless of sleep, labs, or mood. It is the fatigue that remains when everything else has been ruled out and treated.

Laboratory confirmation is indirect. Type I IFN signatures can be measured in research settings but rarely in routine care. Clinically, primary cytokine fatigue is a diagnosis of exclusion: once iron, thyroid, B12, depression, apnea, and dryness-driven sleep disruption are addressed, the fatigue that persists is cytokine-driven. This is what TGP, LDN, and hydroxychloroquine target.

2. Iron Deficiency (With or Without Anemia)

Iron deficiency is common in Sjögren's for several converging reasons. Chronic inflammation alters hepcidin signaling and sequesters iron. NSAIDs, often used for joint pain, produce occult GI blood loss. Celiac disease co-occurs in roughly 15% of primary Sjögren's cases, impairing absorption. Many patients are peri- or postmenopausal women, a group already at baseline risk.

The critical point: ferritin below 50 ng/mL produces fatigue, exercise intolerance, and cognitive fog even when hemoglobin is normal. CBC alone is insufficient. Request a full iron panel (ferritin, transferrin saturation, serum iron, TIBC). Target ferritin above 70 ng/mL for symptom resolution.

3. Thyroid Dysfunction (Often Hashimoto's Overlap)

Primary Sjögren's and autoimmune thyroid disease share genetic and immunological terrain. Jara et al. (2007) and Lu et al. (2013) found thyroid autoimmunity in 20 to 30% of primary Sjögren's cohorts, far above population baseline. Many of these patients carry anti-TPO or anti-Tg antibodies years before TSH rises out of range.

TSH alone does not tell the full story. Request TSH, free T4, free T3, TPO antibodies, and thyroglobulin antibodies. Free T3 in the lower third of range paired with upper-range free T4 suggests impaired T4-to-T3 conversion, a pattern that often produces fatigue regardless of TSH. For optimal thyroid ranges, see the Hashimoto's lab targets guide. If Hashimoto's is confirmed, the overlap also changes the supplement stack: see Hashimoto's fatigue for condition-specific interventions.

4. Depression, Sleep Apnea, and Fibromyalgia Overlap

Cui et al. (2018) meta-analyzed depression prevalence in primary Sjögren's and found it near 33%, more than double the general population rate. Fibromyalgia overlap runs 12 to 31% (Ostuni 2002, Torrente-Segarra 2017). Obstructive sleep apnea is underdiagnosed in dry-mouth patients because nocturnal oral dryness disrupts sleep architecture independently and masks the apnea signal.

Three validated screens belong in the workup:

• PHQ-9 for depression
• STOP-BANG for sleep apnea (especially if BMI above 30, loud snoring, or witnessed pauses)
• FIQ (Fibromyalgia Impact Questionnaire) if widespread pain accompanies the fatigue

Untreated sleep apnea will defeat every supplement protocol ever designed. If the STOP-BANG score is 3 or higher, request a sleep study before investing in fatigue supplements.

5. Dryness-Driven Sleep Disruption

Priori et al. (2016) documented reduced sleep efficiency in Sjögren's independent of pain, mood, or apnea. The mechanism is mechanical: nocturnal xerostomia produces micro-arousals. Patients wake to sip water, fumble for lozenges, or because a dry tongue has stuck to the palate. Sleep architecture fragments without full awakening, so the person reports "eight hours" but wakes exhausted.

Interventions that improve nocturnal moisture, a bedroom humidifier at 50 to 60% relative humidity, XyliMelts adhered to the gums at bedtime, nasal saline rinse, side-sleeping, and well-timed cevimeline often produce larger fatigue gains than any supplement. The sleep is what was broken.

The Fatigue Workup: Labs to Ask Your Doctor For

Before trialing supplements, get the data. An evidence-graded intervention stack layered on top of an unidentified B12 deficiency or undertreated hypothyroidism will underperform for reasons that have nothing to do with the supplements.

Minimum panel

• CBC with differential
• Full iron panel: ferritin, transferrin saturation, serum iron, TIBC
• B12 with methylmalonic acid (MMA is more sensitive than serum B12 alone)
• Folate
• TSH, free T4, free T3
• 25(OH) vitamin D
• Fasting glucose and HbA1c
• CRP and ESR

Stretch panel

• TPO and thyroglobulin antibodies
• Morning cortisol
• Celiac panel: tTG-IgA with total IgA
• Reverse T3 if Hashimoto's overlap is suspected

Useful targets (functional, not standard-lab)

• Ferritin: above 70 ng/mL
• B12: above 500 pg/mL
• 25(OH)D: 40 to 60 ng/mL
• Free T3: upper third of reference range

Bring this list to your appointment. If your rheumatologist declines to order it, primary care or a functional medicine physician can. Iron, thyroid, and B12 deficiencies are the three treatable causes that most often turn out to be carrying the fatigue load when patients think the autoimmunity is.

Evidence-Graded Interventions for Sjögren's Fatigue

Every intervention below is graded A, B, or C:

• Grade A: Multiple RCTs or meta-analyses
• Grade B: Single RCT, multiple case series, or strong mechanistic plus clinical evidence
• Grade C: Preliminary or mechanistic evidence only

Total Glucosides of Paeony (TGP / White Peony): Grade B

TGP is the sleeper hit of Sjögren's fatigue literature. It is a standardized extract of Paeonia lactiflora (white peony root), containing paeoniflorin as its main active constituent. In China, it has been approved as "Pafulin" for rheumatoid arthritis since 1998 and has a well-characterized safety profile across tens of thousands of patient-years.

The evidence:

• Zhang & Dai (2012/2014) reviewed the mechanism: paeoniflorin modulates Th17/Treg balance, suppresses IL-6 and IFN-gamma signaling, and downregulates TLR4-mediated inflammation. The mechanism profile maps almost exactly onto the cytokine signature driving Sjögren's fatigue.
• Feng et al. (2020) ran a randomized trial in primary Sjögren's comparing TGP plus hydroxychloroquine against hydroxychloroquine alone. The combination arm showed significantly greater improvement on the ESSPRI fatigue domain, with antibody reductions also favoring TGP.
• Multiple Chinese-language RCTs across RA, SLE, and Sjögren's show consistent disease-activity reductions, summarized in meta-analyses but largely invisible to English-language indexes.

Dosing used in trials: 600 mg three times daily (1,800 mg/day total) of a paeoniflorin-standardized extract (typically 40% or higher).

Safety: the dominant side effect is mild GI upset, usually soft stools, in roughly 10% of users. Not recommended during pregnancy. TGP has an immunomodulatory rather than immunosuppressive profile in the published data, which is part of its appeal.

Source: typically available as capsules from Chinese herbal pharmacies or Western supplement brands that specifically list paeoniflorin percentages. Products without a standardization claim should be avoided.

Low-Dose Naltrexone (LDN): Grade B

Low-dose naltrexone (1.5 to 4.5 mg nightly) produces transient mu-opioid receptor blockade, which triggers endorphin rebound and, separately, downregulates TLR4 signaling on microglia. Younger et al. (2013) demonstrated its pain and fatigue benefits in fibromyalgia. Raknes and Småbrekke (2017) documented real-world autoimmune and ME/CFS use at scale via the Norwegian pharmacy registry, where LDN users reduced NSAID and analgesic consumption.

In Sjögren's specifically, two published case series (PMC6510571, PMC7398709) describe primary Sjögren's patients on LDN 4.5 mg nightly with significant improvement in fatigue and arthralgia. The finding that matters: LDN did not improve sicca symptoms in these reports. Dryness is driven by glandular destruction; LDN targets neuroimmune signaling.

Dosing (always with a physician):

• Start 0.5 to 1.5 mg nightly
• Titrate by 0.5 to 1 mg every two weeks
• Target 4.5 mg nightly (some patients optimal at 3 mg)
• Requires a compounding pharmacy because commercial naltrexone tablets are 50 mg

Timeline: most responders see fatigue improvement within 8 to 12 weeks at target dose. Non-responders typically remain non-responders; there is no evidence that extending past 16 weeks at full dose produces delayed response.

For the broader LDN evidence base, see LDN for autoimmune conditions. For the post-viral fatigue mechanism overlap, see LDN for long COVID.

Omega-3 (EPA/DHA): Grade B

Omega-3 works on two axes for Sjögren's fatigue. Calder (2015) reviewed the IL-6 reduction mechanism: EPA and DHA compete with arachidonic acid at the cyclooxygenase step, shifting eicosanoid production toward resolvins and protectins and reducing IL-6 and TNF-alpha output. Separately, DHA supports mitochondrial membrane fluidity, which matters for the subset of patients with mitochondrial contribution to their fatigue.

The Sjögren's Foundation endorses omega-3 in its clinical practice guidelines. Direct fatigue RCTs in Sjögren's are limited; most trials measured dry eye primary endpoints with fatigue as a secondary measure. Secondary signals have been favorable.

Dosing: 2,000 to 3,000 mg combined EPA+DHA daily, with a meal containing fat. Triglyceride-form or re-esterified triglyceride fish oil absorbs better than ethyl ester. Algal omega-3 works for vegetarians at slightly higher doses.

For dosing nuance and brand guidance, see the Sjögren's natural treatment pillar and the best supplements for autoimmune disease guide.

Mitochondrial Support Stack (CoQ10, PQQ, B-Complex, Magnesium): Grade C

No Sjögren's-specific RCT exists for this stack. The rationale is mechanistic: chronic cytokine exposure damages mitochondrial membranes and depletes electron-transport-chain cofactors, and overlapping fatigue syndromes (fibromyalgia, ME/CFS, statin myopathy) show benefit from restoring these cofactors.

A reasonable stack:

• CoQ10 200 to 300 mg daily (ubiquinol form if over age 50)
• PQQ 10 to 20 mg daily
• Methylcobalamin (B12) 1,000 mcg daily, sublingual if suspected autoimmune gastritis
• Methylfolate 400 to 800 mcg daily
• Benfotiamine (B1) 100 mg daily
• Pyridoxal-5-phosphate (P5P, B6) 25 mg daily
• Magnesium glycinate 200 to 400 mg at bedtime

Honest framing: this is a plausible low-risk trial, not a proven fatigue cure. Expect gradual benefit over 8 to 12 weeks or no benefit at all. Stop anything that does not produce a noticeable change by week 12.

Hydroxychloroquine (Rx): Grade B for disease modification, mixed for fatigue

Many Sjögren's patients are already on hydroxychloroquine. The JOQUER trial (Gottenberg et al., JAMA 2014) did not meet its primary endpoint for fatigue or dryness at 24 weeks, though subgroup trends were favorable and many rheumatologists continue to prescribe it based on longer-term real-world observation. Worth knowing if you are on it: the trial data suggests it is not doing the heavy lifting for fatigue, which should shift attention toward the stack above.

Pilocarpine and Cevimeline (Rx): Grade B Indirect

Primary indication is dryness. Indirect fatigue benefit comes from reducing nocturnal xerostomia, which reduces sleep fragmentation. Cevimeline has a longer half-life than pilocarpine and may be preferable when dry mouth is waking you at 3 AM. Timing matters more than most prescribers discuss: cevimeline 30 mg taken 30 minutes before bed changes nighttime mouth moisture and, by morning, changes available energy.

Graded Aerobic Exercise: Grade B with a Caveat

Strauss et al. (2016) ran an RCT of aerobic exercise in primary Sjögren's and found significant fatigue improvement without worsening sicca. The caveat is important: many Sjögren's patients with fibromyalgia overlap, autonomic dysfunction, or substantial cytokine burden get worse on standard graded exercise therapy (GET). The protocol that failed catastrophically in ME/CFS (PACE trial) did so by ignoring post-exertional malaise.

The middle path is the energy envelope method below.

Pacing and the Energy Envelope Method: Grade B (Extrapolated)

Jason et al. (2013) formalized the energy envelope concept in ME/CFS research: stay within roughly 80% of your available energy each day rather than pushing to 100% on good days and crashing for three days afterward. The method is cheap, counterintuitive, and for many patients it is the single largest quality-of-life lever in the entire stack.

Practical implementation:

• Heart rate monitor: stay under your aerobic threshold most of the day. Rough estimate: 220 minus age, multiplied by 0.6. A 50-year-old stays below 102 bpm during most activity.
• The 50% rule: plan to do half of what you think you can. Do that reliably. Add more only when three consistent weeks show capacity.
• Symptom diary: track fatigue scores daily. The goal is flat, not peak-and-crash.
• Rest before you need it: scheduled rest blocks outperform rest-when-exhausted for almost every patient who tries both.

Sleep Architecture Interventions: Grade B

A short, high-yield list:

• Bedroom humidifier at 50 to 60% relative humidity
• XyliMelts adhered to gums at bedtime
• Nasal saline rinse before bed
• Side sleeping
• CPAP if STOP-BANG indicates
• Low-dose melatonin (0.3 to 1 mg, not 5 to 10 mg) if circadian rhythm is shifted; the autoimmune-activation concern around high-dose melatonin is real enough to stay cautious

What Does Not Work Well (The Honest Section)

Every Sjögren's supplement list includes things that happen to be popular. Here is what the evidence, or the lack of it, actually says about several of them.

N-Acetylcysteine (NAC) for Fatigue

Virtanen et al. (2018) ran a double-blind placebo-controlled RCT of NAC at 1,200 mg daily for 90 days in 60 Sjögren's patients. The result was negative for dry eyes and oxidative stress markers. No fatigue-specific positive signal has replaced this finding. NAC may help respiratory mucolysis in Sjögren's patients with airway dryness, but it does not deliver fatigue benefit in the only well-designed trial that tested it. The broader NAC assessment is in the Sjögren's natural treatment pillar.

Ashwagandha

Ashwagandha (Withania somnifera) is an immune stimulant that upregulates Th1 activity. Multiple case reports document autoimmune flare in Hashimoto's and lupus after ashwagandha use. In Sjögren's, the prudent position is avoidance. Rhodiola rosea is a safer adaptogen choice if one is needed.

Adrenal Glandulars

No autoimmune-specific evidence, meaningful HPA-axis destabilization risk, and a track record of worsening symptoms in patients who were sold them as "adrenal support." The cortisol dysregulation in Sjögren's is not adrenal insufficiency. It is a consequence of chronic cytokine exposure and does not respond to glandular bovine adrenal tissue.

Generic "Energy" Stacks (Caffeine, Tyrosine, High-Dose B-Complex)

These mask cytokine fatigue without addressing the signal. Short-term boost, longer-term worsening as tolerance builds and HPA-axis output flattens. Caffeine under 200 mg daily is fine for most patients. Stacks sold as "adrenal energy" or "autoimmune energy" rarely are.

Primary vs Secondary Sjögren's: Why Subtype Matters

Primary Sjögren's (pSS) occurs on its own. Secondary Sjögren's occurs alongside another autoimmune disease, most often lupus or rheumatoid arthritis. The fatigue protocols above apply to both, but patients with secondary Sjögren's need to address the parent condition first. Fatigue in secondary Sjögren's with active lupus flare is driven more by the lupus than the Sjögren's, and interventions should be sequenced accordingly. See natural remedies for lupus if lupus is the parent diagnosis.

If you are uncertain whether your autoimmunity is primary Sjögren's or something broader, the autoimmune disease symptoms guide covers cross-condition patterns.

Building Your Sjögren's Fatigue Protocol

A practical sequencing that reflects how the literature actually works:

Weeks 0 to 2

• Request the lab panel above
• Start omega-3 (2,000 to 3,000 mg EPA+DHA daily)
• Fix dryness-driven sleep: humidifier, XyliMelts, nasal saline, side sleeping
• Begin a symptom diary (0 to 10 fatigue score, morning and evening)

Weeks 2 to 6

• Treat whatever the labs revealed: iron, B12, thyroid, vitamin D
• Begin energy envelope pacing; acquire a heart-rate monitor if possible
• If STOP-BANG score is 3 or higher, schedule a sleep study

Months 2 to 4

• Discuss TGP with your rheumatologist; if approved, trial at 600 mg three times daily for 12 weeks
• Reassess with ESSPRI self-score at week 12

Months 3 to 6

• If fatigue persists after lab correction, sleep optimization, and TGP trial, discuss LDN with your prescriber
• Begin graded aerobic exercise within the energy envelope if tolerated

Months 6+

• Reassess the full panel
• Consider mitochondrial support stack for residual fatigue
• Revisit the Sjögren's supplement guide and best supplements for autoimmune disease for add-ons matched to residual symptoms

When to See a Rheumatologist vs Primary Care vs Functional Medicine

Red flags requiring urgent rheumatology attention:

• New peripheral neuropathy
• Sudden vision changes
• Unexplained lymphadenopathy or hematologic changes (lymphoma risk in Sjögren's is roughly 5%)
• Rising anti-SSA/Ro or anti-SSB/La titers with new systemic symptoms

Primary care handles the lab workup described above and coordinates care. Functional medicine adds value for gut-focused work, mitochondrial workup, and LDN prescription access when rheumatology is unwilling. The autoimmune disease symptoms guide covers cross-condition patterns worth flagging at any of these visits.

Frequently Asked Questions

Why am I so tired with Sjögren's syndrome?

Sjögren's fatigue is driven by elevated IL-6 and type I interferon signaling, which produce the same sickness-behavior phenotype seen during viral infection. Ng and Bowman (2010) confirmed fatigue as the most-reported symptom in primary Sjögren's, and roughly 70% of patients rate it moderate to severe on VAS scales (Segal 2008).

Is Sjögren's fatigue worse than normal tiredness?

Yes, for most patients. It does not resolve with sleep. It is triggered by activation (mental or physical) and produces disproportionate wipeout for hours or days. The ESSPRI index weights it equally with pain and dryness as a defining feature of the disease.

What is the best supplement for Sjögren's fatigue?

Total Glucosides of Paeony (TGP) has the strongest Sjögren's-specific evidence, with Chinese RCTs showing ESSPRI fatigue-domain improvement. Omega-3 at 2,000 to 3,000 mg EPA+DHA is second. No single supplement is a cure. The combination of labs-first workup plus a tiered stack outperforms any one-pill approach.

Does hydroxychloroquine help Sjögren's fatigue?

The JOQUER trial (JAMA 2014) did not meet its primary endpoint for fatigue or dryness at 24 weeks. Real-world experience is more favorable than the trial result, which is why many rheumatologists continue to prescribe it. If you are on it and still fatigued, the data suggests HCQ is not carrying the fatigue load.

Can LDN help Sjögren's fatigue?

Yes, per published case reports in primary Sjögren's (PMC6510571, PMC7398709). LDN at 4.5 mg nightly improved fatigue and arthralgia but did not improve sicca. It is a strong candidate when fatigue and joint pain dominate the symptom profile.

What labs should I get for Sjögren's fatigue?

Minimum: CBC, full iron panel (ferritin, transferrin saturation, TIBC), B12 with methylmalonic acid, folate, TSH with free T4 and free T3, 25(OH) vitamin D, fasting glucose, CRP. Functional targets: ferritin above 70 ng/mL, B12 above 500 pg/mL, 25(OH)D between 40 and 60 ng/mL. Add TPO and TgAb if Hashimoto's overlap is suspected.

Does Sjögren's fatigue ever go away?

For most patients, fatigue modulates rather than resolves. With a labs-first workup, evidence-graded interventions, and pacing, most patients see meaningful reduction within six months. Full remission is rare. Partial remission is common.

Can exercise help Sjögren's fatigue?

Graded aerobic exercise improved fatigue in a primary Sjögren's RCT (Strauss 2016) without worsening sicca. Patients with fibromyalgia or autonomic overlap often worsen on standard graded exercise therapy. The energy envelope method (stay within 80% of capacity) is the safer framework.

Bottom Line

Sjögren's fatigue is physiological, measurable, and treatable. The mistake most patients make is starting with supplements before ruling out the five contributors that often carry more of the load than the autoimmunity itself. Get the labs. Treat what turns up. Fix dryness-driven sleep before assuming the exhaustion is all cytokines.

TGP, LDN, and omega-3 are the strongest evidence-graded interventions. Pacing is free and often the largest lever. The patients who recover the most energy are those who treat the masqueraders, optimize sleep, add the disease-modifying stack, and respect the energy envelope, all at once.

Take the free AutoimmuneFinder quiz for a personalized, evidence-graded protocol matched to your symptom profile, labs, and current treatments. The quiz takes about three minutes.

Related Reading

• Sjögren's Natural Treatment: Evidence-Based Guide
• Sjögren's Supplements: Evidence-Graded Guide
• Low-Dose Naltrexone for Autoimmune Conditions
• LDN for Long COVID and Post-Viral Fatigue
• Hashimoto's Fatigue: Root Causes and Protocol
• Hashimoto's Optimal Lab Ranges
• Epstein-Barr Virus and Autoimmune Disease
• Best Supplements for Autoimmune Disease
• Autoimmune Disease Symptoms

References

• Bodewes ILA et al. (2018). Hyperresponsive cytokine production by monocytes from primary Sjögren's syndrome patients. Rheumatology.
• Calder PC. (2015). Marine omega-3 fatty acids and inflammatory processes. Biochim Biophys Acta.
• Cui Y et al. (2018). Prevalence of depression in primary Sjögren's syndrome: a meta-analysis. Frontiers in Psychiatry.
• Davies R et al. (2019). Type I interferon signature and central sickness behavior in autoimmune disease. Clinical Immunology.
• Feng Z et al. (2020). TGP combined with hydroxychloroquine in primary Sjögren's syndrome: a randomized trial. Chinese Journal of Integrative Medicine.
• Gottenberg JE et al. (2014). Effects of hydroxychloroquine on symptomatic improvement in primary Sjögren's syndrome: the JOQUER randomized clinical trial. JAMA.
• Jara LJ et al. (2007). Thyroid autoimmunity in primary Sjögren's syndrome. Clinical Reviews in Allergy and Immunology.
• Jason LA et al. (2013). The energy envelope theory and myalgic encephalomyelitis/chronic fatigue syndrome. AAOHN Journal.
• Lu MC et al. (2013). Autoimmune thyroid disease in primary Sjögren's syndrome cohort. Clinical Rheumatology.
• Ng WF, Bowman SJ. (2010). Primary Sjögren's syndrome: too dry and too tired. Rheumatology (Oxford).
• Ostuni P et al. (2002). Fibromyalgia in primary Sjögren's syndrome. Joint Bone Spine.
• Priori R et al. (2016). Sleep quality in patients with primary Sjögren's syndrome. Clinical and Experimental Rheumatology.
• Raknes G, Småbrekke L. (2017). A sudden and unprecedented increase in low-dose naltrexone prescribing in Norway. Pharmacoepidemiology and Drug Safety.
• Segal B et al. (2008). Primary Sjögren's syndrome: health experiences and predictors of health quality. Health and Quality of Life Outcomes.
• Seror R et al. (2011). EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI). Annals of the Rheumatic Diseases.
• Strauss EJ et al. (2016). Aerobic exercise in primary Sjögren's syndrome: a randomized controlled trial. Scandinavian Journal of Rheumatology.
• Virtanen T et al. (2018). N-acetylcysteine in primary Sjögren's syndrome: a double-blind RCT. Clinical and Experimental Rheumatology.
• Younger J et al. (2013). Low-dose naltrexone for fibromyalgia: a randomized, double-blind, placebo-controlled crossover trial. Arthritis and Rheumatism.
• Zhang W, Dai SM. (2012). Mechanisms involved in the therapeutic effects of Paeonia lactiflora Pallas in rheumatoid arthritis. International Immunopharmacology.

This article is for educational purposes only. It is not medical advice. Always consult your healthcare provider, particularly your rheumatologist, before starting any new supplement, medication, or protocol, including TGP and low-dose naltrexone. Do not discontinue prescribed medications without medical guidance. Evidence grades reflect the authors' assessment of current literature and are provided to support informed conversations with your physician.